A single institutional analysis of systemic therapy for unresectable or recurrent small bowel adenocarcinoma

Shunichiro Makino, Hidekazu Takahashi, Naotsugu Haraguchi, Junichi Nishimura, Taishi Hata, Chu Matsuda, Masakazu Ikenaga, Kohei Murata, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori, Tsunekazu Mizushima

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Background: Small bowel adenocarcinoma (SBA) is rare. For unresectable or recurrent SBA, systemic treatment is the only potentially promising option. Patients and Methods: This retrospective study included 13 patients with SBA treated at our Institute. All patients received fluorouracil-or fluoropyrimidine-based regimens. We analyzed associations between the progression-free interval (PFI) and therapeutic regimen (n=17) and patient characteristics. Results: The 5-year overall survival of patients with SBA was 23.5%. The 5-year relapse-free survival of patients with curatively resected (R0 or R1) SBA (n=6) was 45%. Patients with unresectable or recurrent SBA (n=10) had a median overall survival time of 28.0 months. No factor was significantly associated with PFI, except the number of treatment regimens required: patients that received only one line of treatment survived significantly longer than those receiving multiple lines. Conclusion: Fluorouracil-or fluoropyrimidine-based regimens might effectively treat unresectable or recurrent SBA. We did not investigate any additive agents that might have increased efficacy of these regimens.

Original languageEnglish
Pages (from-to)1495-1500
Number of pages6
JournalAnticancer research
Issue number3
Publication statusPublished - Mar 2017
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'A single institutional analysis of systemic therapy for unresectable or recurrent small bowel adenocarcinoma'. Together they form a unique fingerprint.

Cite this